Notice Information
Notice Title
NHS National Framework Agreement for the supply of products for the treatment of Bleeding Disorders, including Haemophilia B
Notice Description
National Framework Agreement for the supply of products for the treatment of Bleeding Disorders including Haemophilia B. The framework will commence on 1 July 2022 for a period of 24 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 moths. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for a list of the purchasing points.
Lot Information
Lot 18 - Fresh Frozen Plasma
Fresh Frozen Plasma
Options: Option or Options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement, including extension options, will be no more than 48 months
Lot 16 - Prothrombin Complex driedProthrombin Complex dried
Options: Option or Options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement, including extension options, will be no more than 48 months
Lot 15 - Fibrinogen ConcentrateFibrinogen Concentrate
Options: Option or Options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement, including extension options, will be no more than 48 months
Lot 14 - Von willebrands factor - RecombinantVon willebrands factor - Recombinant
Options: Option or Options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement, including extension options, will be no more than 48 months
Lot 17 - Protein C ConcentrateProtein C Concentrate
Options: Option or Options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement, including extension options, will be no more than 48 months
Lot 10 - Factor XIII - Plasma DerivedFactor XIII - Plasma Derived
Options: Option or Options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement, including extension options, will be no more than 48 months
Lot 11 - Factor XIII - RecombinantFactor XIII - Recombinant
Options: Option or Options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement, including extension options, will be no more than 48 months
Lot 9 - Factor XFactor X
Options: Option or Options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement, including extension options, will be no more than 48 months
Lot 8 - Factor IX - High Purity Factor IXFactor IX - High Purity Factor IX
Options: Option or Options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement, including extension options, will be no more than 48 months
Lot 7 - Factor VIII Inhibitor Bypassing FractionFactor VIII Inhibitor Bypassing Fraction
Options: Option or Options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement, including extension options, will be no more than 48 months
Lot 13 - Von willebrands factor - Plasma DerivedVon willebrands factor - Plasma Derived
Options: Option or Options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement, including extension options, will be no more than 48 months
Lot 12 - Factor VIII/ von willebrands factorFactor VIII/ von willebrands factor
Options: Option or Options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement, including extension options, will be no more than 48 months
Lot 6 - Porcine Factor VIII - susoctocog alfaPorcine Factor VIII - susoctocog alfa
Options: Option or Options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement, including extension options, will be no more than 48 months
Lot 5 - Recombinant Factor VIIRecombinant Factor VII
Options: Option or Options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement, including extension options, will be no more than 48 months
Lot 4 - rFIX - Standard Half LiferFIX - Standard Half Life
Options: Option or Options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement, including extension options, will be no more than 48 months
Lot 3 - nonacog beta pegol (rFIX EHL)nonacog beta pegol (rFIX EHL)
Options: Option or Options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement, including extension options, will be no more than 48 months
Lot 2 - albutrepenonacog alfa (rFIX EHL)albutrepenonacog alfa (rFIX EHL)
Options: Option or Options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement, including extension options, will be no more than 48 months
Lot 1 - eftrenonacog alfa (rFIX EHL)eftrenonacog alfa (rFIX EHL)
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. Total maximum framework agreement including extension options will be no more than 48 months
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-030881
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/018165-2022
- Current Stage
- Award
- All Stages
- Tender, Award
Procurement Classification
- Notice Type
- Tender Notice
- Procurement Type
- Framework
- Procurement Category
- Goods
- Procurement Method
- Open
- Procurement Method Details
- Open procedure
- Tender Suitability
- Not specified
- Awardee Scale
- Large, SME
Common Procurement Vocabulary (CPV)
- CPV Divisions
33 - Medical equipments, pharmaceuticals and personal care products
-
- CPV Codes
33141530 - Blood coagulants
Notice Value(s)
- Tender Value
- £500,000,000 £100M-£1B
- Lots Value
- £18 Under £100K
- Awards Value
- Not specified
- Contracts Value
- £1
Notice Dates
- Publication Date
- 4 Jul 20224 years ago
- Submission Deadline
- 14 Feb 2022Expired
- Future Notice Date
- Not specified
- Award Date
- 15 Jun 20224 years ago
- Contract Period
- 1 Jul 2022 - 30 Jun 2024 2-3 years
- Recurrence
- Not specified
Notice Status
- Tender Status
- Complete
- Lots Status
- Cancelled
- Awards Status
- Active
- Contracts Status
- Active
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- NHS England
- Additional Buyers
The NHS Commissioning Board (operating under the name of NHS England)
- Contact Name
- Available with D3 Tenders Premium →
- Contact Email
- Available with D3 Tenders Premium →
- Contact Phone
- Available with D3 Tenders Premium →
Buyer Location
- Locality
- LEEDS
- Postcode
- LS2 7UE
- Postcode Area
- Leeds
- Country
- England
-
- Major Region (ITL 1)
- TLE Yorkshire and The Humber
- Basic Region (ITL 2)
- TLE4 West Yorkshire
- Small Region (ITL 3)
- TLE42 Leeds
- Delivery Location
- Not specified
-
- Local Authority
- Leeds
- Electoral Ward
- Little London & Woodhouse
- Westminster Constituency
- Leeds Central and Headingley
Further Information
Open Contracting Data Standard (OCDS)
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.